

Chairman's 2023 Annual General Meeting Address

Good afternoon ladies and gentlemen. Welcome to the 2023 AGM for NeuroScientific Biopharmaceuticals Limited. My name is Paul Rennie, the Chairman of NeuroScientific. I will also Chair today's meeting. Thank you for taking the time to attend this afternoon.

It is now 12.00pm and there being a quorum present, I declare the meeting open for business. I confirm that the meeting has been properly constituted.

In opening the 2023 AGM I would like to introduce you to your Board of Directors: Dr Anton Uvarov, Mr Clarke Barlow and Mr Chris Ntoumenopoulos. Mr Stephen Quantrill is an apology for today's meeting. The member of the Board standing for re-election today is myself, Paul Rennie with Mr Clarke Barlow and Mr Chris Ntoumenopoulos standing for election. I would also like to introduce the CEO Mr Steven Carter and the CFO & Company Secretary Ms Abby Macnish.

As this meeting is being conducted as a virtual meeting, I would like to welcome those shareholders that are joining us via zoom and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your zoom screen.

Please start your question by typing your shareholding SRN or HIN. This will allow the moderator to identify you as a shareholder. If you would like to ask your question verbally, type your SRN or HIN and then type "I'd like to speak".

Once you have finished typing, please hit enter on your keyboard to send. When you submit a question or comment please start by typing which resolution it relates to so that it can be addressed at the appropriate time.

Questions which relate to the general business of the Company will be collected and addressed after the close of the formal business of the meeting.

Steve will now present a short update presentation and an opportunity for general questions and answers, before moving to the formal aspects of the meeting.

-ENDS-

For more information please contact:

Paul Rennie
Interim CEO & Chairman
NeuroScientific Biopharmaceuticals
ir@neuroscientific.com
+ 61 8 6382 1805

Lucas Robinson
Investor Relations
Corporate Storytime
lucas@corporatetorytime.com
+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.



NeuroScientific
BIOPHARMACEUTICALS

NOVEL DRUG THERAPIES FOR
NEURODEGENERATIVE CONDITIONS

Annual General Meeting

30 NOVEMBER 2023 · ASX: NSB

neuroscientific.com



DISCLAIMER



The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

BOARD AND MANAGEMENT



Paul Rennie
Chairman and Interim CEO

- Founder of Paradigm (ASX: PAR)
- Former COO of Mesoblast (ASX: MSB)



Dr Anton Uvarov
Non-Executive Director

- Founding Director of Actinogen (ASX: ACW)
- Former equities analyst with Citigroup, US



Stephen Quantrill
Non-Executive Director

- 20+ years corporate advisory
- Executive Chairman of McRae Investments



Abby Macnish Niven
Company Secretary & CFO

- 15+ years as an investment professional



Chris Ntoumenopoulos
Non-Executive Director

- Managing Director at Twenty 1 Corporate, a boutique corporate advisory firm. He is also a director of various private and public companies which span across finance, technology and medical sectors.



Clarke Barlow
Non-Executive Director

- Clarke is a Financial Adviser and Capital Markets Specialist with over 20 years' experience in the Financial Services Industry in Australia and the United Kingdom.



Stephen Carter
Chief Executive Officer

- Experienced pharmaceutical executive with 30 years+ experience in senior roles in drug development and commercialisation

FINANCIAL METRICS AND MILESTONES



FINANCIALS

- ~\$4M cash on hand
- R&D Tax refund due
- Sufficient cash to develop lead project to clinical trials.

TARGET MILESTONES*

- Q1 2024 – Lodge Pre-IND meeting request with FDA
- Q2 2024 – Completion of 13-week GLP tox study in rabbits
- Q4 2024 – Completion of ocular IND-enabling safety studies
- Q3 2024 – Phase I Ocular clinical study
- Q2 2025 – Phase 2 Ocular clinical study
- Q4 2025 – License out EmtinB™ Ocular project

* Milestone target dates may be subject to change due to feedback from the FDA and reliance on independent contract research organisations to undertake and successfully complete each stage.

CAPITAL STRUCTURE

ASX code	NSB
Shares on issue	143M
Price	\$0.07
Market cap	\$10.01M
McRae Investments Pty Ltd	18%
BNP Paribas Noms Pty Ltd	13%
Top Twenty	53%

COMPANY HIGHLIGHTS 2022-2023




- Sept 2022
 - HREC decision to not approve Phase 1 trial
 - CEO Resigns
- Nov 2022
 - Paul Rennie takes over CEO role whilst an international search was started for a new CEO
 - NSB focuses all its efforts on overcoming the deficiencies identified by the HREC.
 - Safety
 - Purity
 - Efficacy
 - NSB engages independent subject matter experts to address the HREC concerns.
 - Most concerns addressed confirming that the drug was safe, and the purity of the drug was acceptable.

COMPANY HIGHLIGHTS 2022-2023 (con't)



NSB continues to review new licensing opportunities

- Dec 2022
 - New Patent application lodged
- Mar 2023
 - NSB commences Phase 0 Study Investigating Exploratory Immune Cell Response of EmtinB™ following Ex Vivo Stimulation of Human Blood
- Aug 2023
 - NSB Employs new CEO
 - CEO reviews EmtinB™ program
- Oct 2023
 - NSB presents future plan for EmtinB™
 - NSB not to progress developing EmtinB™ for the Systemic use of EmtinB™
 - NSB to focus on Neurodegenerative diseases of the eye.
 - NSB to request Type B pre-IND meeting with FDA



STIMULATES CELL SURVIVAL PATHWAYS

Activates cell survival pathways by specifically binding to the LRP-1 transmembrane receptor



PROMOTES AXONAL REGENERATION

Activation of LRP-1 also promotes regeneration of axons of damaged neurons and formation of synaptic connections



REGULATES INFLAMMATION

Downregulates inflammatory responses from activated immune cells (macrophages and glial cells)



PROMOTES REMYELINATION

Stimulates proliferation and differentiation of myelin producing cells (oligodendrocytes)

Comparison of Systemic and Ophthalmology programs



Description	Systemic treatment (Multiple Sclerosis)	Ophthalmology
Safety	Safe	Safe
Efficacy	Data supports efficacy, though uncertainty still exists as to whether we can reach target site	Data supports efficacy. Confirmed ability to reach target sites.
Dosage	Daily	Monthly
Mechanism of Action	Binds to LRP-1	Binds to LRP-1
Route of Administration	Sub Cutaneous	Intra vitreal
Bioavailability	Approx. 24-36 hours	>14 days
Treatment administered by	Self	Doctor
Suitable commercial formulation	Uncertain	Yes
Sufficient stability for intended use	Suitable for Phase 1 study but uncertain whether suitable for commercial use can be achieved	Yes
Cost	High	Low
Market Size	MS <2 million WW	Glaucoma 80million WW 5% of world population has a neurodegenerative eye disease.
Health economic modelling	Challenging viability	Commercially viable
Orphan Drug opportunity	No	Yes
Ability to get new IP	Potentially challenging	Potentially

EMTINB™ promotes survival of retinal ganglion cells and protects the optic nerve




- We evaluated where EmtinB™ was distributed in the eye. The study confirmed that EmtinB™ was distributed through-out the eye and was seen in the optic nerve and nerve head. There were no signs of toxicity.
- We have carried out a number of studies looking at the neuroprotective and neuroregenerative abilities of EmtinB™. These studies looked at the ability of EmtinB™ to trigger known signalling pathways in the eye. We saw significant initiation of the main neuroprotective and regenerative pathways.


ESTABLISHED OCULAR PK & TISSUE PENETRATION

RETINAL TISSUE

Retina, 6-hours




Retina, 9-hours




OPTIC NERVE

Optic nerve head, 6-hours




Optic nerve head, 9-hours




RETINAL TISSUE

24-hours




6-days




OPTIC NERVE TISSUE

24-hours





6-days




EMTINB™ OCULAR DATA

Neuroprotection and regeneration of the optic nerve



GLAUCOMA PIG MODEL

- EmtinB™ demonstrated neuroprotection in glaucoma IOP pig model
- High intraocular pressure pig model is the closest experiment to replicate severe human glaucoma pathology; **positive results in this model indicate disease modifying potential of EmtinB™**
- EmtinB™ treatment showed statistically significant **positive increases (in red)** in the expression levels of all **neurofilaments** and **cytoskeleton** components



GLAUCOMA OPPORTUNITY



- Glaucoma is the leading cause of irreversible blindness in Australia
- Glaucoma is rapidly increasing in prevalence due to an aging population.
- The global prevalence of glaucoma reached 80 million in 2020 with six million of these patients bilaterally blind.
- The prevalence of glaucoma in Australia is estimated to be 3.7%, which increases to 10% in patients over the age of 80. This prevalence is projected to increase by 80% by 2025.
- It is estimated that approximately 50% of Australians with glaucoma do not know they have the disease.
- This is even greater in minority and/or socioeconomically disadvantaged groups, which have up to 4.4 times greater odds of undiagnosed and/or untreated glaucoma.





Figure.

Stages of retinal disease that reflect when neuroprotective strategies should be started to provide the most benefit. The black line shows the hypothetical progression of retinal disease through adaptive, early and late pathology. During early pathology, retinal disease is detectable and potentially reversible while irreversible damage occurs in late-stage pathology. Starting neuroprotective treatments at the first signs of retinal disease would provide the most benefit in preserving vision

COMMERCIALISATION STRATEGY



The Company's commercialisation strategy involves developing its drug candidates through to successful completion of Phase II clinical studies and then license them to a pharmaceutical or biotechnology company for further clinical development / market approval.



SUMMARY



- The Company has conducted an EmtinB™ project review & confirms EmtinB™ as highly prospective as NSB's lead project.
- EmtinB™ is an exciting lead project with significant therapeutic potential.
- EmtinB™ for the treatment of neurodegenerative diseases of the eye has shown great promise.
- >5% of the global population suffer vision loss due to damaged optic nerve representing huge addressable market opportunity.
- Ocular disease has outstanding health economic profile.
- EmtinB™ development for ocular diseases is commercially viable.
- NSB will focus on developing EmtinB™ for the treatment of Glaucoma and other neurodegenerative diseases of the eye.
- NSB has the management and leadership expertise to develop and commercialise EmtinB™.



NeuroScientific
BIOPHARMACEUTICALS

neuroscientific.com

For more information please contact:

Stephen Carter

Chief Executive Officer

sc@neuroscientific.com